Loading institutional data...
Loading institutional data...
Strong institutional distribution: ownership decreased -81.93% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 2 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
How a revenue dollar becomes profit — FY2024
Each value shows its share of revenue below it (common-size).
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $169.1M 100.0% | $28.0M 100.0% | $0 | $0 | $22.3M 100.0% | $59.2M 100.0% | $103.3M 100.0% | $173.2M 100.0% | $150.2M 100.0% | $173.0M 100.0% |
| Cost of Revenue | $15.3M 9.0% | $846K 3.0% | $0 | $0 | $5.7M 25.7% | $12.1M 20.5% | $17.5M 17.0% | $16.3M 9.4% | $13.2M 8.8% | $11.4M 6.6% |
| Gross Profit | $153.8M 91.0% | $27.1M 97.0% | $0 | $0 | — | — | — | — | — | — |
| Research & Development | $15.2M 9.0% | $13.3M 47.4% | $20.7M | $17.1M | $20.4M 91.5% | $32.9M 55.6% | $39.3M 38.1% | $33.4M 19.3% | $34.6M 23.0% | $25.6M 14.8% |
| Selling, General & Admin | $181.0M 107.1% | $151.7M 542.5% | $74.5M | $68.5M | $32.4M 145.1% | $30.2M 51.0% | $100.4M 97.2% | $58.9M 34.0% | $44.2M 29.4% | $21.7M 12.5% |
| Total Operating Expenses | $196.2M 116.0% | $165.0M 589.9% | $98.6M | $85.5M | $16.5M 74.0% | $83.3M 140.7% | $208.2M 201.6% | $83.7M 48.3% | $155.2M 103.3% | $102.3M 59.1% |
| Operating Income | -$42.4M -25.1% | -$137.8M -493.0% | -$98.6M | -$85.5M | $5.8M 26.0% | -$24.1M -40.7% | -$104.9M -101.6% | $89.5M 51.7% | -$5.0M -3.3% | $70.8M 40.9% |
| Interest Expense | $10.8M 6.4% | $9.9M 35.4% | $12.3M | $9.9M | $13.0M 58.2% | $12.5M 21.1% | $10.6M 10.3% | $1.1M 0.6% | $963K 0.6% | $0 0.0% |
| Other Income (Expense), net | — | — | — | $0 | -$435K -1.9% | -$378K -0.6% | $1.9M 1.8% | $2.1M 1.2% | -$6.5M -4.4% | -$4.9M -2.8% |
| Pretax Income | -$49.1M -29.0% | -$160.8M -575.0% | -$111.4M | -$93.1M | -$5.1M -22.8% | -$38.6M -65.2% | -$113.2M -109.6% | $92.7M 53.5% | -$9.7M -6.5% | $77.7M 44.9% |
| Income Tax Expense | -$247K -0.1% | -$501K -1.8% | $26.0M | -$15.8M | -$12.1M -54.2% | -$5.4M -9.0% | -$17.9M -17.3% | $24.4M 14.1% | $31.6M 21.0% | $35.9M 20.8% |
| Net Income | -$48.8M -28.9% | -$160.3M -573.2% | -$137.5M | -$77.3M | $7.0M 31.5% | -$33.2M -56.1% | -$95.3M -92.3% | $68.3M 39.4% | -$41.3M -27.5% | $41.8M 24.2% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.51 | $-2.00 | $-2.29 | $-1.32 | $0.13 | $-0.89 | $-2.55 | $1.69 | $-1.00 | $1.03 |
| EPS (Diluted) | $-0.51 | $-2.00 | $-2.29 | $-1.32 | $0.13 | $-0.89 | $-2.55 | $1.63 | $-1.00 | $0.96 |
| Weighted Avg Shares (Basic) | 95.1M | 80.2M | 60.1M | 58.5M | 53.0M | 37.4M | 37.3M | 40.5M | 41.2M | 40.6M |
| Weighted Avg Shares (Diluted) | 95.1M | 80.2M | 60.1M | 58.5M | 54.9M | 37.4M | 37.3M | 41.8M | 41.2M | 43.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
3/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81 · book equity (no price)
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$47M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -66%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $51M covers the $20M due within a year 2.6× over. Scheduled principal only (excludes interest & revolver draws). As of 2015-06-30 (6-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
No current price collected.
Where each multiple sits in its own 13-yr range
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 13-yr history.
Is the profit real, and how strong is the balance sheet?
FY2024 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 9.4 | 17.0 | 20.5 | 25.7 | — | — | 3.0 | 9.0 |
| Gross Profit | — | — | — | — | — | — | 97.0 | 91.0 |
| R&D | 19.3 | 38.1 | 55.6 | 91.5 | — | — | 47.4 | 9.0 |
| SG&A | 34.0 | 97.2 | 51.0 | 145.1 | — | — | 542.5 | 107.1 |
| Operating Income | 51.7 | -101.6 | -40.7 | 26.0 | — | — | -493.0 | -25.1 |
| Income Tax | 14.1 | -17.3 | -9.0 | -54.2 | — | — | -1.8 | -0.1 |
| Net Income | 39.4 | -92.3 | -56.1 | 31.5 | — | — | -573.2 | -28.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on AVDL: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| AVDL | — | — | — | — | 505% | 91.0% | -28.9% | -66.1% | -66.1% | — | 1 |
Peers = companies sharing AVDL's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.